Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 2,704 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Autologous hematopoietic stem cell transplantation Clear all
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

NCT00003386
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BCG vaccine, autologous tumor cell vaccine, carboplatin, cisplatin, cyclophosphamide, paclitaxel, dinitrophenyl, surgical procedure
Biological · Drug · Other + 1 more
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 31, 2026, 10:30 PM EDT
Recruiting Phase 3 Interventional

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

NCT06588413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplantation
Interventions
Olanzapine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

NCT00772486
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
ISF35
Biological
Lead sponsor
Memgen, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Phase 2 Interventional

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

NCT00080886
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, carmustine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 31, 2026, 10:30 PM EDT
Not yet recruiting Phase 1 Interventional

GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)

NCT07513194
View directory record Official record
Conditions
Atypical Teratoid Rhabdoid Tumor, Central Nervous System Rhabdoid Tumor
Interventions
21.15.GPC3-CAR T Cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 31, 2026, 10:30 PM EDT
Withdrawn Not applicable Interventional

Sensation After Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer

NCT03135392
View directory record Official record
Conditions
Mastectomy, Breast Reconstruction
Interventions
Breast Reconstruction with Artificial Implant, Autologous Breast Reconstruction, Neurotization
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 31, 2026, 10:30 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip

NCT02844764
View directory record Official record
Conditions
Osteoarthritis
Interventions
[StroMed + platelet rich plasma (PRP)]
Biological
Lead sponsor
VivaTech International, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Grove City, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts

NCT01572298
View directory record Official record
Conditions
Dental Alveolus, Oral Surgical Procedures, Preprosthetic
Interventions
allograft alone, allograft with autograft
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma

NCT03398200
View directory record Official record
Conditions
Myeloma
Interventions
Hyperbaric Oxygen Therapy, No Hyperbaric Oxygen Therapy
Biological · Other
Lead sponsor
Omar Aljitawi
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Fairway, Kansas • Lexington, Kentucky • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

NCT03570892
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Phase 2 Interventional

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

NCT00002475
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Interventions
allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide
Biological · Drug
Lead sponsor
St. Vincent Medical Center - Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 31, 2026, 10:30 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

NCT02756728
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BI-505, High dose melphalan, Autologous stem cell transplantation
Biological · Other
Lead sponsor
BioInvent International AB
Industry
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 31, 2026, 10:30 PM EDT
Not listed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System

NCT00626314
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
myoblast, sham
Biological
Lead sponsor
Mytogen, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gilbert, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 29, 2008 · Synced Oct 31, 2026, 10:30 PM EDT
Not listed Not applicable Interventional

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

NCT03135184
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia, HoFH
Interventions
HDL Therapeutics PDS-2 System
Device
Lead sponsor
HDL Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Blood Transfusion in Healthy Volunteers

NCT01226498
View directory record Official record
Conditions
Blood Transfusion, Autologous
Interventions
Red blood Cells auto-transfusion
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Assessment of Bone Augmentation in Post-Extraction Sockets

NCT00641316
View directory record Official record
Conditions
Unrestorable Dentition, Post-Extraction Sockets
Interventions
AtraumaticTeeth Extraction, Atraumatic Teeth Extraction/Grafted Extraction Sockets
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 31, 2026, 10:30 PM EDT
Withdrawn Phase 1 Interventional

19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction

NCT02035085
View directory record Official record
Conditions
Breast Cancer
Interventions
CS-1000 labeled SVF cells
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Lutherville-Timonium, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

NCT03812263
View directory record Official record
Conditions
Leukocyte Adhesion Defect - Type I
Interventions
RP-L201
Biological
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
3 Months and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 31, 2026, 10:30 PM EDT
Enrolling by invitation No phase listed Observational

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

NCT04049084
View directory record Official record
Conditions
Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency (SCID)
Interventions
autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 31, 2026, 10:30 PM EDT
Completed No phase listed Observational

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study

NCT00001255
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
ADA PBSC, ADA Umbilical Cord Blood Cells, Transduced Lymphocytes
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 10:30 PM EDT
Withdrawn Not applicable Interventional

Autologous Regenerative Technology (ART) For Wound Healing

NCT03368534
View directory record Official record
Conditions
Chronic Wounds
Interventions
Autologous Regenerative Technology (ART)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 31, 2026, 10:30 PM EDT
Withdrawn Not applicable Interventional

Hair Transplantation for Treatment of Vitiligo

NCT04858152
View directory record Official record
Conditions
Vitiligo
Interventions
Follicular Unit Extraction via punch biopsy
Procedure
Lead sponsor
Mehdi Rashighi
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 31, 2026, 10:30 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

NCT00046852
View directory record Official record
Conditions
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 31, 2026, 10:30 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair

NCT02825849
View directory record Official record
Conditions
Infertility, Asherman's Syndrome
Interventions
Intrauterine infusion of platelet rich plasma
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 31, 2026, 10:30 PM EDT